- According to new research, a technique for reading the genetic abnormalities in patient tumors with a simple blood test has passed a critical test of accuracy and reliability.
- New research shows patients with non-metastatic ovarian cancer live longer when chemotherapy is delivered into the abdomen instead of by standard intravenous infusion, yet only a minority of eligible patients are receiving it.
- Results from a study evaluating an oral daily dose of the drug enobosarm, shows promise for women with metastatic, androgen receptor positive, estrogen receptor positive breast cancer.
Tags: BreastCancer, TargetedTherapy
- Dana-Farber researchers report new data point to the lasting benefit, for many patients, of the targeted drug imatinib which has revolutionized the treatment of advanced gastrointestinal stromal tumors.
Tags: Sarcoma, TargetedTherapy
- F. Stephen Hodi, MD, and colleagues report the immunotherapy drug nivolumab continues to show long-term effectiveness in treating metastatic melanoma, achieving a three-year survival rate of 41 percent against the deadly skin cancer.
Tags: Melanoma, Immunotherapy
- Ursula Matulonis, MD, and colleagues report a two-drug combination that disrupts critical signaling circuits in cancer cells has produced an observable benefit in patients with recurrent high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).
Tags: BreastCancer, CervicalCancer
- One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure (CHF) finds improved health outcomes but suggests that less frequent screening than currently recommended may yield similar clinical benefit.
Tags: ChildhoodCancer, Survivorship
- Scientists at Dana-Farber Cancer Institute have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.
Tags: Antibody, BasicResearch
- A study 10 years ago discovered a gene mutation that could be treated by a drug that was on the market for something else and changed the way lung cancer patients are treated. It was the start of the era of precision medicine in lung cancer and transformed treatment of the disease.
Tags: EGFR, LungCancer, TargetedTherapy
- Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a targeted drug for advanced stomach cancer.
Tags: chemotherapy, TargetedTherapy
Showing 31-40 of 525 items